AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own POET Technologies, you really have to believe its Optical Interposer platform can convert today’s small revenue base and large losses into sustainable, scaled demand across AI, data center and networking customers. The near term story is still about execution: hitting the 2026 production ramp, turning joint developments with partners like Lumilens, Lessengers and Lite-On into firm orders, and managing heavy cash burn after sizeable equity raises and dilution. On that score, the additions of Dr. Bardia Pezeshki and Jean F. Rankin look incrementally helpful but not transformational in the short run; they mainly strengthen technical oversight and governance as POET pushes toward high volume manufacturing. The bigger risks remain unchanged: limited current revenue, ongoing losses, legal overhang from the class action, insider selling and high share price volatility.
However, one key operational risk could matter much more than recent board changes for shareholders. In light of our recent valuation report, it seems possible that POET Technologies is trading beyond its estimated value.Explore 6 other fair value estimates on POET Technologies - why the stock might be worth as much as 97% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com